Skip to main content
Premium Trial:

Request an Annual Quote

Inpharmatica Licenses Biopendium Database to Chugai Pharmaceutical

NEW YORK, Sept. 20 (GenomeWeb News) - Inpharmatica, through its partner PharmaDesign, has licensed its Biopendium database to Chugai Pharmaceutical of Japan, the company said today.


Chugai decided to take an online subscription to Biopendium, the protein annotation component of Inpharmatica's PharmaCarta platform. Biopendium provides sequence annotations for over 150 organisms.


Chugai is the fourth Japanese subscriber to Biopendium, according to London-based Inpharmatica.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.